Decentralized trials company Science 37 to go private in deal with diagnostics startup eMed

Science 37, one of the startups that fueled the rise in decentralized clinical trials, will go private and see its one-time $1 billion valuation evaporate to just a $38 million equity value in an all-cash deal with eMed.

The telehealth and diagnostics company eMed, which gained popularity during the pandemic…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks